Open label, four-period, two-sequence, fully replicated, randomized, single dose pivotal study for the assessment of bioequivalence between Furosemide 500 mg tablets (Test) and Lasix 500 mg tablets (Reference) in healthy male volunteers under fasting conditions
Phase 1
- Conditions
- ot applicable. The study will be conducted on healthy volunteers.Therapeutic area: Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]Therapeutic area: Diseases [C] - Male Urogenital Diseases [C12]
- Registration Number
- CTIS2023-505335-12-00
- Lead Sponsor
- Ratiopharm GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method